By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.

Czech steam-turbine manufacturer Doosan Skoda Power AS launched an initial public offering, touting an outlook for high ...

The IPO share allotment will be finalised by January 28, while investors can start trading in CLN Energy shares on the BSE ...

On , Beijing Time, Qiming Venture Partners' portfolio company HyperStrong, a leading provider of battery energy storage systems (BESS) in China, successfully debuted on the Shanghai Stock Exchange's ...

Shares of Nvidia, Broadcom, and ASML slump as China’s DeepSeek threatens the companies’ dominance in artificial intelligence, ...

Rexpro Enterprises IPO shows a grey market premium of ₹10, indicating a potential listing price of ₹155. The IPO was ...

Luxury logistics leader Ferrari Group Plc (NYSE:RACE) has announced plans to debut on the Amsterdam Stock Exchange with an ...

Bengaluru-based cloud kitchen startup Curefoods is preparing to launch its $300-400 Mn IPO in the latter half of FY26.

Chandhiok & Mahajan and Dentons Link Legal are acting on Vidya Wires' Limited proposed Initial Public Offering (IPO) ...

In an interaction with Fortune India, Dr. Adil Agarwal, CEO of Dr Agarwal's Healthcare, shared his views on India’s eye care ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...